SecBot SecBot
8-K ·Filed Sep 2, 2026

PHR

Phreesia, Inc.
BEARISH
Impact 6/10
Horizonweeks Processed2mo ago SEC0001412408-26-000213
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

The EPS miss and maintained lowered guidance reinforce the bearish narrative from the prior quarter's guidance cut. Monitor the Q3 FY2027 earnings for signs of stabilization in network solutions revenue and the pace of restructuring savings realization.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$11.10
T+0 close · Sep 2, 2026 · via day close
Latest settled
−9.28%
T+20 · $10.07 · next T+60 in 13d
Vs SPY
−8.09%
α at T+20
Latest observation
+13.71%
T+50 · FF3 residual α
  1. T+0 · Sep 3 $11.10entry
  2. T+1 · 2mo ago −1.44%α −1.06% · $10.94
  3. T+5 · 2mo ago −7.12%α −5.97% · $10.31
  4. T+20 · 7w ago −9.28%α −8.09% · $10.07
  5. T+51 · todayOpen
  6. T+60 · in 13d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Phreesia reported Q2 FY2027 revenue of $129.5M (+10% YoY), in line with consensus, but GAAP EPS of $0.03 was a significant miss vs the $0.10 Street consensus. The company maintained its lowered FY2027 revenue guidance of $510-520M and EBITDA guidance of $125-135M, citing ongoing variability in network solutions revenue from pharma budget pullbacks. A restructuring plan eliminating ~220 positions was implemented in May 2026, with $2.8M in charges recognized this quarter. The stock faces headwinds from the EPS miss, guided revenue deceleration, and a history of poor post-earnings performance.

Key Financial Metrics

EPS
$0.03
est $0.10 · -70.0%
Revenue
$129.5M
est $129.0M · +0.4% · +10.4% YoY
Rating
miss
Guidance
$510M-$520M
maintained
Free Cash Flow
$13.8M

Key Facts

  • Total revenue of $129.5M, up 10% YoY, in line with consensus of $129.0M
  • GAAP diluted EPS of $0.03, missing Street consensus of $0.10 by ~70%
  • Subscription revenue declined 2% YoY to $52.7M; payment solutions grew 36% to $38.5M; network solutions grew 9% to $38.3M
  • FY2027 revenue guidance maintained at $510-520M (implying ~flat to -3% YoY at midpoint), lowered from prior $545-559M in March 2026
  • Adjusted EBITDA of $32.9M, up 49% YoY; FY2027 EBITDA guidance maintained at $125-135M
  • Restructuring plan announced May 7, 2026: ~220 positions eliminated, ~$10M total charges expected; $2.8M recognized in Q2
  • Debt reduced by $23.5M during Q2; $60.7M outstanding on $275M Capital One credit facility as of July 31, 2026
  • Free cash flow of $13.8M, up from $9.6M in prior year quarter

Financial Impact

GAAP EPS of $0.03 vs $0.10 consensus (-70% miss); revenue in line at $129.5M; FY2027 revenue guidance cut to $510-520M from $545-559M (midpoint -6.5%)

epsrevenueguidancedebt

Risk Factors

  • Network solutions revenue variability from pharma budget pullbacks (vaccines, GLP-1, public health) may persist or worsen
  • Subscription revenue decline (-2% YoY) signals potential client churn or pricing pressure
  • Restructuring execution risk: ~220 positions eliminated may disrupt operations or client relationships
  • Elevated debt ($60.7M) and interest expense ($1.7M in Q2) limit financial flexibility

Market Snapshot

Exchange
NYSE
Sector
Services-Business Services, NEC
Analyst Consensus
61% bullish (23 analysts)

Investment Themes

Software & IT

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001412408-26-000213
Document: phr-ex992q2fy27stakehold.htm0001412408-26-000213
Document: phr-20260902.htm0001412408-26-000213
Document: 0001412408-26-000213-index-headers.html0001412408-26-000213
Document: 0001412408-26-000213-index.html0001412408-26-000213
Document: 0001412408-26-000213.txt0001412408-26-000213
8-K Data (Synthetic)0001412408-26-000213

Track record

8 reports on PHR

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +6.45% at T+5 after the Apr 3, 2026 report. 1 of 4 went positive at some point.

Filters
  1. Nov 13, 20263d ago SC 13G/A Bearish 4/10 Entry $12.69 Now $12.82 −1.02% settles Nov 20
  2. Oct 27, 202620d ago SC 13G Neutral 3/10 Entry $12.37 to $13.18 Now $12.82 +3.64% ▲ +6.55% +7.26% vs SPY
  3. Sep 2, 202610w ago 8-K Bearish 6/10 Viewing Entry $11.10 to $10.31 Now $12.82 −15.50% ▲ +7.12% +5.97% vs SPY
  4. May 14, 202626w ago DEFA14A Neutral 3/10 Entry $8.77 to $8.92 Now $12.82 +46.18% ▲ +1.71% +0.75% vs SPY
  5. Apr 10, 202631w ago Insider Cluster Bearish 4/10 Entry $8.06 to $9.17 Now $12.82 −59.06% ▼ −13.77% −9.27% vs SPY
  6. Apr 10, 202631w ago Insider Cluster Bearish 6/10 Entry $8.06 to $9.17 Now $12.82 −59.06% ▼ −13.77% −9.27% vs SPY
  7. Apr 3, 202632w ago 8-K Bearish 8/10 Entry $9.15 to $8.56 Now $12.82 −40.11% ▲ +6.45% +10.58% vs SPY
  8. Mar 18, 202634w ago Insider Cluster Neutral 4/10 Entry $11.20 to $11.28 Now $12.82 +14.46% ▲ +0.71% +1.43% vs SPY
Showing 8 of 8

US Market Status

Market Closed · Opens Wed (11h 17m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 2, 2026